Form 4 El-Hibri Fuad For: Aug 11 (10K)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0287
Expires:	February 28, 2011
Estimated average burden
hours per response		0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

El-Hibri Fuad

(Last)

(First)

(Middle)

2273 RESEARCH BLVD, SUITE 400

(Street)

ROCKVILLE

20850

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [EBS]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
CEO & Chairman

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2009

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/11/2009		S		700	D	$ 16.92	14,300 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		100	D	$ 16.91	14,200 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		6,000	D	$ 16.9	8,200 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		700	D	$ 16.83	7,500 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		1,800	D	$ 16.75	5,700 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		100	D	$ 16.7	5,600 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		1,000	D	$ 16.68	4,600	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		100	D	$ 16.67	4,500 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		700	D	$ 16.66	3,800 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		702	D	$ 16.64	3,098 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		800	D	$ 16.63	2,298 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		1,400	D	$ 16.62	898 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		400	D	$ 16.61	498 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock	08/11/2009		S		498	D	$ 16.6	0 ⁽¹⁾	I	By Intervac Management, L.L.C.
Common Stock								5,011 ⁽²⁾	I	By Karim El-Hibri Trust
Common Stock								5,011 ⁽²⁾	I	By Yusra El-Hibri Trust
Common Stock								5,011 ⁽²⁾	I	By Faiza El-Hibri Trust
Common Stock								7,181,835 ⁽³⁾	I	By Intervac, L.L.C.
Common Stock								2,965,043 ⁽⁴⁾	I	By BioPharm, L.L.C.
Common Stock								1,599,155 ⁽⁵⁾	I	By Biovac, L.L.C.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Explanation of Responses:

1. Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 4,666 shares and his right to receive a preferred return upon the liquidation of Intervac Management, L.L.C.

2. These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. Mr. El-Hibri holds, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Intervac, L.L.C. is the direct owner of 7,181,835 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein in 2,731,079 shares.

4. Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 2,965,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,191,057 shares.

5. Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.

	/s/ Carl A. Valenstein, attorney-in-fact	08/12/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Add to Delicious

Digg It

Send by Email

View Comments (0)

Post Comment